Bp PLC Biomarin Pharmaceutical Inc Transaction History

Bp PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$74.77 - $85.47 $337,137 - $385,384	-4,509 Closed	0 $0
Q2 2021 Aug 09, 2021	SELL	$75.51 - $84.79 $145,281 - $163,135	-1,924 Reduced 29.91%	4,509 $376,000
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $134,663 - $163,423	-1,802 Reduced 21.88%	6,433 $486,000
Q4 2020 Feb 08, 2021	SELL	$72.61 - $90.2 $643,687 - $799,623	-8,865 Reduced 51.84%	8,235 $721,000
Q3 2020 Oct 30, 2020	SELL	$71.87 - $131.03 $100,618 - $183,442	-1,400 Reduced 7.57%	17,100 $1.3 Million
Q4 2019 Feb 07, 2020	BUY	$64.27 - $86.37 $1.19 Million - $1.6 Million	18,500 New	18,500 $1.56 Million
Q1 2019 May 08, 2019	SELL	$84.2 - $98.62 $1.6 Million - $1.87 Million	-19,000 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$80.14 - $106.07 $240,420 - $318,210	-3,000 Reduced 13.64%	19,000 $1.62 Million
Q2 2018 Jul 30, 2018	BUY	$76.01 - $99.03 $1.67 Million - $2.18 Million	22,000 New	22,000 $2.07 Million
Q1 2018 Apr 26, 2018	SELL	$77.67 - $92.63 $1.55 Million - $1.85 Million	-20,000 Closed	0 $0
Q3 2017 Oct 30, 2017	BUY	$80.6 - $94.95 $1.61 Million - $1.9 Million	20,000	20,000 $1.86 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Bp PLC, based on Form 13F filings with the SEC.

Stay updated on Bp PLC with notifications on news.